Wimmesberger Nicole, Rau Diana, Schuchardt Florian, Meier Simone, Herrmann Matthias L, Bergmann Ulrike, Farin-Glattacker Erik, Brich Jochen
Section Health Care Research and Rehabilitation Research, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg im Breisgau, Germany.
Department of Neurology and Neurophysiology, Medical Centre - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
JMIR Res Protoc. 2024 Feb 13;13:e51683. doi: 10.2196/51683.
Endovascular thrombectomy (ET), combined with intravenous thrombolysis if possible, is an effective treatment option for patients with stroke who have confirmed anterior large vessel occlusion (aLVO). However, ET is mainly limited to comprehensive stroke centers (CSCs), resulting in a lack of ET capacity in remote, sparsely populated areas. Most stroke networks use the "Drip and Ship" or "Mothership" strategy, resulting in either delayed ET or intravenous thrombolysis, respectively.
This study protocol introduces the Leitstellen-Basierte Erkennung von Schlaganfall-Patienten für eine Thrombektomie und daraufhin abgestimmte Optimierung der Rettungskette (LESTOR) strategy, developed to optimize the preclinical part of the stroke chain of survival to improve the clinical outcome of patients with suspected aLVO stroke. This involves refining the dispatch strategy for identifying patients with acute aLVO stroke using a phone-based aLVO query. This includes dispatching emergency physicians and emergency medical services (EMS) to urban emergency sites, as well as dispatching helicopter EMS to remote areas. If a highly suspected aLVO is identified after a standardized aLVO score evaluation during a structured examination at the emergency scene, prompt transport to a CSC should be prioritized.
The LESTOR study is a controlled, nonrandomized study implementing the LESTOR strategy, with a stepped-wedge, cluster trial design in 6 districts in southwest Germany. In an interprofessional, iterative approach, an aLVO query or dispatch protocol intended for use by dispatchers, followed by a coordinated aLVO examination score for use by EMS, is being developed, evaluated, and pretested in a simulation study. After the training of all participating health care professionals with the corresponding final aLVO query, the LESTOR strategy is being implemented stepwise. Patients otherwise receive usual stroke care in both the control and intervention groups. The primary outcome is the modified Rankin Scale at 90 days in patients with stroke receiving endovascular treatment. We will use a generalized linear mixed model for data analysis. This study is accompanied by a cost-effectiveness analysis and a qualitative process evaluation.
This paper describes and discusses the protocol for this controlled, nonrandomized LESTOR study. Enrollment was completed in June 2023. Data analysis is ongoing and the first results are expected to be submitted for publication in 2024. The project started in April 2020 and will end in February 2024.
We expect that the intervention will improve the clinical outcome of patients with aLVO stroke, especially outside the catchment areas of CSCs. The results of the accompanying process evaluation and the cost-effectiveness analysis will provide further insights into the implementation process and allow for a better interpretation of the results.
German Clinical Trials Register DRKS00022152; https://drks.de/search/de/trial/DRKS00022152.
INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID): DERR1-10.2196/51683.
血管内血栓切除术(ET),若可能则联合静脉溶栓,是确诊为前循环大血管闭塞(aLVO)的卒中患者的一种有效治疗选择。然而,ET主要局限于综合卒中中心(CSC),导致偏远、人口稀少地区缺乏进行ET的能力。大多数卒中网络采用“点滴转运”或“母舰”策略,分别导致ET延迟或仅进行静脉溶栓。
本研究方案介绍了基于卒中中心的急性缺血性卒中患者识别及后续优化急救流程(LESTOR)策略,该策略旨在优化生存卒中链的临床前部分,以改善疑似aLVO卒中患者的临床结局。这涉及优化调度策略,通过基于电话的aLVO查询来识别急性aLVO卒中患者。这包括向城市急救地点派遣急诊医生和紧急医疗服务(EMS),以及向偏远地区派遣直升机EMS。如果在急诊现场进行结构化检查并经标准化aLVO评分评估后确定为高度疑似aLVO,应优先将患者迅速转运至CSC。
LESTOR研究是一项实施LESTOR策略的对照、非随机研究,采用阶梯式楔形整群试验设计,在德国西南部的6个地区开展。采用跨专业的迭代方法,正在开发、评估并在模拟研究中预测试供调度员使用的aLVO查询或调度协议,随后开发供EMS使用的协调aLVO检查评分。在对所有参与的医疗保健专业人员进行相应的最终aLVO查询培训后,逐步实施LESTOR策略。对照组和干预组的患者在其他方面均接受常规卒中护理。主要结局是接受血管内治疗的卒中患者90天时的改良Rankin量表评分。我们将使用广义线性混合模型进行数据分析。本研究还伴有成本效益分析和定性过程评估。
本文描述并讨论了这项对照、非随机的LESTOR研究的方案。入组于2023年6月完成。数据分析正在进行中,预计首批结果将于2024年提交发表。该项目于2020年4月启动,将于2024年2月结束。
我们预计该干预措施将改善aLVO卒中患者的临床结局,尤其是在CSC服务区域之外。伴随的过程评估和成本效益分析结果将为实施过程提供进一步见解,并有助于更好地解释研究结果。
德国临床试验注册中心DRKS00022152;https://drks.de/search/de/trial/DRKS00022152。
国际注册报告识别码(IRRID):DERR1-10.2196/51683。